Welcome to our dedicated page for Park Ha Biological Technology Co., Ltd. SEC filings (Ticker: BYAH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Park Ha Biological Technology Co., Ltd.'s SEC filings document the regulatory record of a Cayman Islands foreign private issuer with operating subsidiaries that sell Park Ha skincare and cosmetic products in China. Current reports on Form 6-K cover Nasdaq listing compliance, board changes, shareholder voting matters and amendments to its memorandum and articles.
The company's filings also describe its capital structure, including Class A ordinary shares, Class B ordinary shares with higher voting rights, warrants issued in public offerings, securities purchase agreements, placement agency arrangements and Form F-1 registration statement disclosures. These records connect financing activity and share-capital matters to BYAH's public-company governance and reporting obligations.
Park Ha Biological Technology Co., Ltd. reported the initial holdings of its COO, Wang Li (Alya), in a Form 3. She beneficially owns 187,500 Class A Ordinary Shares, held directly. These shares were purchased under the company’s 2026 Share Incentive Plan and the reported amount reflects a 1-for-8 reverse stock split effected on August 6, 2026.
Zhu Xiaoyan reported acquisition or exercise transactions in this Form 4 filing.
Park Ha Biological Technology Co., Ltd. reported that CFO Zhu Xiaoyan received a grant of 112,500 Class A Ordinary Shares on August 3, 2026 at $0.18 per share, purchased from the company under its 2026 Share Incentive Plan. Following this award, she directly holds 112,500 shares. The reported share amounts reflect a 1-for-8 reverse stock split effective August 6, 2026.
Park Ha Biological Technology Co., Ltd. expects to implement a 1-for-8 reverse stock split of its Class A and Class B ordinary shares. Subject to Nasdaq Operations notice requirements, the split is expected to take effect on August 6, 2026, with trading beginning on a split-adjusted basis that day. Issued and outstanding ordinary shares will be consolidated from 18,764,216 to 2,345,527. The pre-split figure reflects 10,000,000 Class A shares issued in an August 3, 2026 private placement and 2,400,000 Class A shares issued under the 2026 Share Incentive Plan, and excludes up to 2,000,000 Class A shares issuable upon cashless warrant exercise.
No fractional shares will be issued; any fractional entitlement will be rounded up so each affected holder receives one whole post-split ordinary share. Authorized share capital will remain US$300,000,000.00 but will change from 300,000,000,000 ordinary shares at US$0.001 par value to 37,500,000,000 shares at US$0.008 par value. Class A ordinary shares will continue to trade on the Nasdaq Capital Market under “BYAH” with a new CUSIP, and no other material changes to the terms of the securities are anticipated.
Park Ha Biological Technology Co., Ltd. completed a Regulation S private placement with non-U.S. investors on August 3, 2026. The company issued 10,000,000 Class A ordinary shares, par value US$0.001, together with warrants to purchase up to 2,000,000 additional Class A shares, at a purchase price of US$0.18 per share and accompanying warrant, generating approximately US$1,800,000 in gross proceeds before expenses.
The warrants are immediately exercisable, carry a five-year term from issuance, and have an exercise price of US$0.18 per warrant share. The warrant terms state that the exercise price and warrant share count will not be adjusted for future share dividends, splits, combinations, recapitalizations or similar transactions. The securities were sold in offshore transactions to non-U.S. persons under Regulation S and are subject to transfer restrictions during the applicable distribution compliance period. The company plans to use the net proceeds for general working capital and corporate purposes.
Park Ha Biological Technology Co., Ltd. reported net revenue of $1,257,689 for the six months ended April 30, 2026, up 1% from $1,239,197, with overall gross margin at 96%. Revenue mix shifted toward product sales to non‑franchise customers, which rose 188% to $600,022, while franchise fees fell 35% to $541,584 as franchisees declined to 21 from 39.
Operating expenses excluding prior share‑based compensation increased, notably selling and marketing (up 144% to $560,577), research and development ($138,618), and allowance for expected credit losses ($286,048, mainly on franchisee loans). Because a $19,950,000 share‑based payment recorded in 2025 did not recur, the net loss narrowed sharply to $918,282 from $19,835,994. Cash and cash equivalents decreased to $627,851 as $5,029,644 was placed in short‑term bank investments; total current assets were $6,783,004 against total liabilities of $2,073,806.
Park Ha Biological Technology Co., Ltd. reports that shareholders approved extensive capital and governance changes at an Extraordinary General Meeting and a Class A Meeting held on July 13, 2026. As of the July 2, 2026 record date, 6,364,216 shares were issued, including 5,983,216 Class A Ordinary Shares and 381,000 Class B Ordinary Shares.
Shareholders approved increasing authorised share capital from US$3,000,000 (3,000,000,000 ordinary shares) to US$300,000,000 (300,000,000,000 ordinary shares), comprising 240,000,000,000 Class A and 60,000,000,000 Class B shares of par value US$0.001 each. The Board was authorised, for three years, to carry out share consolidations with an aggregate ratio between 2-for-1 and 5,000-for-1, and share subdivisions between 2-for-1 and 100-for-1.
All resolutions at the EGM passed with over 10.28 million votes in favour versus about 22,000 against. Class A shareholders and the sole Class B holder separately approved increasing the voting rights of each Class B share from 20 votes to 100 votes. A new Amended and Restated Memorandum and Articles of Association reflecting these changes was adopted.
Park Ha Biological Technology Co., Ltd. filed a Form 6-K to report that its North American Amazon store has been officially approved and all registration procedures are complete. This means the company can begin selling its skincare products directly to consumers through Amazon’s North American marketplace.
The company describes this step as a key milestone in its global expansion strategy, saying the Amazon onboarding process involved strict standards around brand qualifications, compliance, and market reputation. It views the approval as recognition of its brand strength, product competitiveness, and operational systems.
Park Ha plans to use Amazon as its primary international platform, relying on Fulfillment by Amazon logistics and data tools to tailor products for North American consumers and increase brand visibility. The company, founded in 2016, currently operates five directly owned stores and supports 22 franchisees in China under its “Park Ha” skincare brand.
Park Ha Biological Technology Co., Ltd. is asking shareholders to approve a major increase in authorised share capital to 300,000,000,000 ordinary shares, split into 240,000,000,000 Class A and 60,000,000,000 Class B shares, each with US$0.001 par value.
The company is also seeking three-year authority for the board to execute dual-class share consolidations (reverse splits) with aggregate ratios between 2-for-1 and 5,000-for-1, and dual-class share subdivisions between 2-for-1 and 100-for-1, without further shareholder votes, subject to Nasdaq rules. Shareholders are asked to adopt amended and restated memorandum and articles that, among other changes, formalize these mechanics and meeting procedures.
Separately, Class A shareholders and the sole Class B holder are being asked to approve a variation that would increase the voting power of each Class B Ordinary Share from 20 votes to 100 votes, significantly strengthening the super-voting class while Class A shares remain at one vote each. Record-date outstanding shares were 5,930,216 Class A and 381,000 Class B as of July 2, 2026.
Park Ha Biological Technology Co., Ltd. has filed a complete membership application with the Personal Care Products Council (PCPC), a leading North American personal care trade association. The application includes corporate qualifications, raw material compliance documentation, and product safety materials, which are under review.
The company describes this step as pivotal for building a compliance framework for the North American market and supporting its planned entry into Amazon’s North America marketplace. Through PCPC’s regulatory expertise and industry network, Park Ha Biological aims to strengthen its international expansion strategy. The company, established in 2016, currently operates five directly owned stores and works with 22 franchisees in China as of October 31, 2025.
Park Ha Biological Technology Co., Ltd. is advancing its global expansion by starting cooperation with Amazon North America and preparing to enter the North American personal care market. The company is simultaneously working on store qualification registration, Amazon brand registry enrollment, a North American compliance framework, and localized product strategies, with progress described as ahead of schedule.
This move is framed as a key step in its overseas online business and a way to tap into Amazon’s roughly 310 million annual active buyers in North America. Park Ha Biological currently operates five directly owned stores and has 22 franchisees in China as of October 31, 2025, and aims to extend its Eastern-inspired, science-based skincare offerings to a broader global audience.